TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

100 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • DepressionAnxiety

    Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

    Testing whether therapy sessions can help teens and young adults with sickle cell cope with

    📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →

    The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.

    ✓ Study care freePhase 1Ages 14–21Learn more →
  • Depression

    The Role of mGluR5 in CBT-I

    Testing how a brain receptor may affect CBT-I for insomnia in people with depression

    📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →

    This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

    Testing brain scan and EEG measures to predict response to depression treatment

    📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →

    The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

    Testing whether a brain receptor change affects ketamine’s effect on depression

    📍 Yale University · New Haven, CT · Get directions →

    The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Sickle cell disease

    A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

    Testing different doses of DISC-3405 to check safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Depression

    Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

    Testing how dimethyltryptamine affects safety and depression symptoms

    📍 Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT · Get directions →

    The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects.

    ✓ Study care freePhase 1Ages 21–65Learn more →
  • Depression

    Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

    Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and

    📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →

    The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?

    ✓ Study care freePhase 4Ages 65+Learn more →
  • Depression

    Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

    Testing whether a low-dose ketamine IV treatment is safe and workable in the ER for people with

    📍 University of Kansas Strawberry Hill Campus · Kansas City, KS · +1 more US site · Get directions →

    There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Depression

    Dopaminergic Therapy for Anhedonia - 2

    Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation

    📍 Emory University Hospital · Atlanta, GA · Get directions →

    The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.

    ✓ Study care freePhase 4Ages 25–55Learn more →
  • Anxiety

    Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy

    Testing whether self-controlled nitrous oxide during vasectomy lowers pain and anxiety

    📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →

    This study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. If we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (SANO) may be a useful tool for improving experience of care during vasectomy.

    ✓ Study care freePhase 4Ages 21–85MenLearn more →
  • Depression

    Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression

    Testing how one-time exercise and ibuprofen affect bipolar depression symptoms

    📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →

    This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • DepressionAnxiety

    ACT for Individuals With MNCD and Their Care Partners

    Testing acceptance commitment therapy for depression and anxiety in dementia

    📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →

    This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

    Testing higher doses of VAS-101 in people with stable sickle cell disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • Depression

    RCT of Psilocybin-assisted CBT for Depression

    Testing psilocybin with cognitive-behavioral therapy for depression

    📍 UCLA Semel Institute · Los Angeles, CA · Get directions →

    The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.

    ✓ Study care freePhase 1Ages 21–60Learn more →
  • Depression

    Identifying and Treating Depression in the Orthopaedic Trauma Population

    Testing how orthopedic trauma teams can screen for depression and treat it with medication

    📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →

    The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Depression

    Psilocybin for Treatment-Resistant Depression in Autism

    Testing psilocybin plus talk therapy for depression in autistic adults

    📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →

    We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Depression

    DBS for Depression

    Testing whether deep brain stimulation is safe and feasible for severe depression that hasn’t

    📍 Zucker Hillside Hospital · Queens, NY · Get directions →

    The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression?

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • Depression

    Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

    Testing whether donor stem cells are safe and helpful for hard-to-treat bipolar depression

    📍 The University of Texas Health Science Center at Houston · Houston, TX · Get directions →

    The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Depression

    Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

    Comparing best step-by-step treatments for depression with anxiety

    📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →

    Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.

    ✓ Study care freePhase 4Ages 18–50Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Depression

    Pharmacologic Augmentation of TMS for Depression With D-serine

    Testing whether adding D-serine to TMS sessions helps depression

    📍 McLean Hospital · Belmont, MA · Get directions →

    The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Anxiety

    Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

    Testing whether genetic-guided dosing of a daily anxiety medicine helps kids

    📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →

    This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.

    ✓ Study care freePhase 4Ages 12–17Learn more →
  • Anxiety

    Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

    Testing whether adding L-methylfolate is safe and tolerated for hard-to-treat anxiety

    📍 Kingston Health Sciences Centre · Kingston, Ontario · Get directions →

    The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    Neural Response to Inflammatory Challenge in Major Depressive Disorder

    Testing brain and immune responses to an inflammation trigger in depression

    📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →

    This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Depression

    Neural Circuit Effects of Ketamine in Depression

    Testing how ketamine affects brain activity and depression symptoms

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    Comparing a drug called AXS-05 with bupropion to prevent depression relapse

    📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • DepressionAnxiety

    Open-Label Psilocybin Study in Transdiagnostic Population

    Testing psilocybin for safety and symptom changes in people with depression or anxiety

    📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →

    The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionAnxiety

    Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

    Testing a chatbot to support people using cannabis with anxiety or depression

    📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →

    This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Depression

    Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

    Testing a biomarker prediction tool to forecast depression treatment outcomes

    📍 University of Calgary · Calgary, Alberta · Get directions →

    This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Anxiety

    The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

    Testing whether focused ultrasound thalamotomy can improve anxiety

    📍 The Ohio State University · Columbus, OH · Get directions →

    The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Depression

    Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

    Testing how psilocybin affects the brain in people with hard-to-treat bipolar depression

    📍 Toronto Western Hospital - University Health Network · Toronto, Ontario · Get directions →

    This study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and integration psychotherapy sessions (psilocybin-assisted psychotherapy, or PAP). Using fMRI (functional magnetic resonance imaging), the findings of this study will provide data on the neurobiological mechanism of psilocybin in TRBD.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Gene Editing For Sickle Cell Disease

    Testing whether gene editing is safe for people with sickle cell disease

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.

    ✓ Study care freePhase 1Ages 18–24Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Testing ways to stop prediabetes and obesity from getting worse

    💵 May compensate

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Depression

    Theta-Burst Stimulation to Treat Depression

    Testing a non-invasive brain stimulation approach to treat depression

    📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →

    The goal of this clinical trial is to explore the effects of non-invasive brain stimulation protocols using intermittent theta-burst stimulation (iTBS) on brain plasticity and depression severity in depressed individuals aged 18 to 50 years old. Brain plasticity is the brain's ability to change through growth or reorganization.

    ✓ Study care freePhase 1Ages 18–50Learn more →
  • Depression

    Personalized Ultrasonic Brain Stimulation for Depression (R61)

    Testing a personalized, noninvasive brain stimulation for depression

    📍 University of Utah · Salt Lake City, UT · Get directions →

    This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Depression

    A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression

    Testing ketamine with group therapy for Spanish-speaking adults with depression

    📍 Massachusetts General Hospital, Chelsea · Chelsea, MA · Get directions →

    This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression

    ✓ Study care freePhase 1Ages 18–64Learn more →
  • Depression

    Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

    Studying how menstrual hormone changes affect mood and reward in women with depression

    📍 University of North Carolina, Chapel Hill · Chapel Hill, NC · Get directions →

    The goal of this clinical trial is to learn how hormonal changes over the menstrual cycle affect mood symptoms in reproductive-aged women with depression that worsens during the premenstrual period. The main questions it aims to answer are: --How do fluctuations in estradiol and progesterone across the menstrual cycle affect the ability to experience pleasure and the neural sensitivity to reward in hormone-sensitive, depressed women?

    ✓ Study care freePhase 4Ages 18–45WomenLearn more →
  • Sickle cell disease

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Testing how BMS-986470 affects the body and safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Depression

    PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

    Testing PET brain scans to study how nicotine may affect depression

    📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →

    In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Sickle cell disease

    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    Testing a partial stem cell transplant from matched donors for severe sickle cell disease or

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens.

    ✓ Study care freePhase 1Ages 4–65Learn more →
  • Sickle cell disease

    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

    Testing how safe escalating doses of fostamatinib are in people with stable sickle cell disease

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

    Testing gene editing in stem cells for severe sickle cell disease

    📍 Boston Children's Hospital · Boston, MA · Get directions →

    A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease.

    ✓ Study care freePhase 1Ages 13–40Learn more →
  • Depression

    📍 Neurocrine Clinical Site · Bryant, AR · +21 more US sites · Get directions →

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Psilocybin in Chronic Low Back Pain and Depression

    Testing psilocybin’s effects on chronic low back pain and depression

    📍 Johns Hopkins University School of Medicine · Baltimore, MD · Get directions →

    This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose).

    ✓ Study care freePhase 1Ages 21–80Learn more →
  • Sickle cell disease

    SCD Stem Cell Mobilization and Apheresis Using Motixafortide

    Testing whether motixafortide is safe and can raise stem cells in people with sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +2 more US sites · Get directions →

    This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Depression

    Esketamine With or Without Integration Therapy for Treatment-Resistant Depression

    Testing whether nasal esketamine with or without therapy helps adults with depression that hasn’t

    📍 Pravan Foundation · San Juan, · Get directions →

    This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD). All participants will receive esketamine as prescribed by a healthcare professional in a clinical setting.

    ✓ Study care freePhase 4Ages 21–65Learn more →
  • Depression

    Pattern Separation in Major Depressive Disorder

    Testing how depression treatments affect thinking, brain activity, and symptoms

    📍 New York State Psychiatric Institute (NYSPI) · New York, NY · Get directions →

    This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

    ✓ Study care freePhase 1Ages 18–50Learn more →
  • Depression

    Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

    Testing whether EEG gamma activity can predict 4-week ketamine treatment results for depression

    📍 Wells Medicine · Houston, TX · +1 more US site · Get directions →

    The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion.

    ✓ Study care freePhase 1Ages 21–45Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    FES Cycling With BFR in the Spinal Cord Injury Population

    Testing a cycling exercise program with added arm-leg pressure for people with spinal cord injury

    📍 Lyndhurst Centre · Toronto, Ontario · Get directions →

    Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Sickle cell disease

    Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

    Testing different ways to use hydroxyurea for treating sickle cell anemia

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA.

    ✓ Study care freePhase 4Ages 1+Learn more →
  • Sickle cell disease

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

    Testing the safety and effects of panobinostat in adults with sickle cell disease

    📍 Augusta University · Augusta, GA · Get directions →

    The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Sickle cell disease

    A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

    Testing how a new medicine works in healthy people and sickle cell patients

    📍 University of Alabama Birmingham · Birmingham, AL · +5 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).

    ✓ Study care freePhase 1Ages 12–55Learn more →
  • Depression

    Personalized Indications for CBT and Antidepressants in Treating Depression

    Testing how cognitive-behavioral therapy and antidepressant use can be matched for people with

    📍 Nova Scotia Health Authority · Halifax, Nova Scotia · Get directions →

    Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Showing the first 60 of 100. Add filters or a location to narrow down.